Company intelligence / Profile preview

Reflection Biotechnologies

Ownership: Private
Development stage: Other

Overview

Actively advancing gene therapy R&D for Bietti’s Crystalline Dystrophy; preclinical scientific publications and patient-driven research collaborations have yielded promising molecular data but no completed clinical trials to date

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

RBIO-101

Preclinical

Partnerships

International Rare Diseases Research Consortium (IRDiRC) Task Force (indirect collaboration via founder)

Beyond the preview

Go deeper on Reflection Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reflection Biotechnologies.